LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

Search

REVOLUTION Medicines Inc

Aperta

SettoreSettore sanitario

37.5 -0.5

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

36.91

Massimo

37.8

Metriche Chiave

By Trading Economics

Entrata

-19M

-213M

EPS

-1.13

Margine di Profitto

-74.379

Dipendenti

616

EBITDA

-24M

-237M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+83.88% upside

Dividendi

By Dow Jones

Utili prossimi

6 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-126M

7.5B

Apertura precedente

38

Chiusura precedente

37.5

Notizie sul Sentiment di mercato

By Acuity

69%

31%

347 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 giu 2025, 23:49 UTC

Utili

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 giu 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 giu 2025, 21:30 UTC

Utili

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 giu 2025, 21:07 UTC

Utili

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 giu 2025, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 giu 2025, 23:39 UTC

Discorsi di Mercato

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 giu 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 giu 2025, 23:33 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 giu 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 giu 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 giu 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 giu 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 giu 2025, 23:30 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 giu 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 giu 2025, 23:19 UTC

Acquisizioni, Fusioni, Takeovers

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 giu 2025, 22:06 UTC

Utili

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 giu 2025, 21:15 UTC

Utili

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 giu 2025, 21:07 UTC

Utili

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 giu 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 giu 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 giu 2025, 21:06 UTC

Discorsi di Mercato

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 giu 2025, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 giu 2025, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 giu 2025, 20:52 UTC

Utili

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 giu 2025, 20:51 UTC

Utili

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 giu 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

REVOLUTION Medicines Inc Previsione

Obiettivo di Prezzo

By TipRanks

83.88% in crescita

Previsioni per 12 mesi

Media 70.63 USD  83.88%

Alto 80 USD

Basso 57 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per REVOLUTION Medicines Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

10

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

40.67 / 41.96Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

347 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.